Regeneron Pharma (REGN) PT Cut at Baird on 'Uneventful Earnings'
November 4, 2016 12:40 PM
Baird analyst Brian Skorney lowered his price target on Neutral-rated Regeneron Pharma (NASDAQ: REGN) to $379.00 (from $448.00) following "uneventful ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
